NEW YORK , Nov. 1, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The global rare hematology market size is estimated to grow by USD 4.58 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 5.7% during the forecast period. Enhancement of strategic portfolios is driving market growth, with a trend towards approvals from food and drug administration (FDA).
However, high treatment costs poses a challenge.Key market players include AbbVie Inc., AstraZeneca Plc, Bayer AG, Biogen Inc.
, bluebird bio Inc., Bristol Myers Squibb Co., CSL Ltd.
, Emmaus Medical Inc., F. Hoffmann La Roche Ltd.
, GlaxoSmithKline Plc, Grifols SA, Jazz Pharmaceuticals Plc, Johnson and Johnson Services Inc., Merck and Co. Inc.
, Novartis AG, Novo Nordisk AS, Octapharma AG, Pfizer Inc., Sanofi SA, and Takeda Pharmaceutical Co. Ltd.
. AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View your snapshot now Key Market Trends Fueling Growth The global rare hematology market is significantly driven by approvals from the Food and Drug Administration (FDA).
These approvals shape treatment landscapes and fuel market growth. In February 2023 , Sanofi and Sobi received early FDA approval for Altuviiio, an extended half-life factor VIII replacement therapy for hemophilia A. This approval, based on positive phase 3 XTEND-1 study results, sets Altuviiio apart with its .
